Engineered t cells take on Hard-to-Treat breast cancer
NCT ID NCT05989828
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a new cell therapy for people with advanced triple negative breast cancer that has stopped responding to standard treatments. The therapy uses the patient's own immune cells, which are modified in a lab to recognize and attack cancer cells carrying a specific marker called NY-ESO-1. The study aims to find the safest dose and check for side effects in about 20 participants.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TRIPLE NEGATIVE BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
USC / Norris Comprehensive Cancer Center
RECRUITINGLos Angeles, California, 90033, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a High-Fiber diet shield the gut during breast cancer therapy?
- Can mapping tumor DNA unlock personalized breast cancer care?
- Can a Two-Pronged antibody boost Chemo's power against a tough breast cancer?
- Can a new drug rally the immune system against Hard-to-Treat cancers?
- Could an oral chemo pill improve breast cancer treatment?
- Can a new nucleotide analogue boost cancer treatment?